Shares of Akebia Therapeutics (NASDAQ:AKBA) surged 24% after the company reported Q1 results.Quarterly Results Earnings per share fell 6.82% year over year to ($0.47), which beat the estimate of ($0.62).Revenue of $88,478,000 up by 21.76% year over year, which beat the estimate of $77,480,000.Looking Ahead Akebia Therapeutics hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 05, 2020View more earnings on AKBATime: 01:05 PM ETWebcast URL: https://edge.media-server.com/mmc/p/tni8ok36Price Action 52-week high: $10.53Company's 52-week low was at $2.99Price action over last quarter: Up 24.78%Company Overview Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.See more from Benzinga * Recap: Vericel Q1 Earnings * Recap: eXp World Holdings Q1 Earnings * Recap: Peapack-Gladstone Financial Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Q1 2020 Akebia Therapeutics Inc Earnings Call
Shares of Akebia Therapeutics Inc. gained 30% in premarket trading on Tuesday after the drugmaker reported positive topline results from a Phase 3 trial for patients with chronic kidney disease. The experimental drug, vadadustat, is aimed at treating anemia c…
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will participate in the Jefferies Virtual Global Healthcare Conference on Tuesday, June 2 at 8:00 a.m. ET. A live webcast and replay of Akebia's presentation will be available on the Company's website at www.akebia.com.
Company hits 52-week high of $12.25 Continue reading...
AKBA earnings call for the period ending March 31, 2020.
Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced positive top-line results from INNO2VATE, its global Phase 3 cardiovascular outcomes program evaluating the efficacy and safety of vadadustat, its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), versus darbepoetin alfa for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. (Please refer to Akebia's INNO2VATE Data Announcement for the top-line data.) The Company also reported financial results for the first quarter ended March 31, 2020 and will host a conference call with slides today, Tuesday, May 5, 2020, at 8:30 a.m. Eastern Time to discuss INNO2VATE top-line data, its first quarter financial results and recent business highlights.
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted eight newly-hired employees options to purchase an aggregate of 95,300 shares…
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 25.40% and 14.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will participate in the 2020 RBC C…
As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA).
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will participate in the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20 at 10:20 a.m. ET. A live webcast and replay of Akebia's presentation will be available on the Company's website at www.akebia.com.
Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced positive top-line results from INNO2VATE, its global Phase 3 cardiovascular outcomes program evaluating the efficacy and safety of vadadustat, its investigational oral hypoxia-inducible factor prolyl h…
David Abrams’ 13F portfolio value decreased this quarter from $3.22B to $2.54B. The number of positions increased from 21 to 22.Abrams Capital Management added TransDigm Group while dropping O’Reilly Automotive during the quarter.The top three positions are P…
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, announced today that its collaboration partner, Japan Tobacco, Inc. (JT), has filed a…
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted eight newly-hired employees options to purchase an aggregate of 95,300 shares of Akebia's common stock on April 30, 2020, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will participate in the Jefferies …
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of an underwritten public offering of 11,000,000 shares of common stock at a public of…
Shares of Akebia Therapeutics Inc. gained 30% in premarket trading on Tuesday after the drugmaker reported positive topline results from a Phase 3 trial for patients with chronic kidney disease. The experimental drug, vadadustat, is aimed at treating anemia caused by the kidney disease and was tested in the trial in comparison with Amgen's Aranesp, a longtime blockbuster drug that brought in $1.7 billion in 2019. This is the first of two late-stage clinical studies for vadadustat. In this trial, the investigational drug met the primary and secondary efficacy endpoints and the first safety endpoint, Akebia said. Akebia's stock is up 37% year-to-date, while the S&P 500 is down 12%.
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, announced today that its collaboration partner, Japan Tobacco, Inc. (JT), has filed a supplemental New Drug Application (NDA) with the Pharmaceuticals and Medical Devices Agency (PMDA) seeking an additional indication for Riona® Tablets 250mg (generic name in Japan: ferric citrate hydrate) to treat adult patients with iron deficiency anemia (IDA) in Japan. JT and its subsidiary, Torii Pharmaceutical Co., Ltd. (Torii), made a public announcement, which is available here: https://www.torii.co.jp/en/release/2020/20200515_E1.pdf.
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the underwriters of its previously announced public offering, which closed on May 14, 2020, have exercised in full their option to purchase an additional 1,650,000 shares of its common stock at the public offering price of $12.00 per share, less underwriting discounts and commissions. After giving effect to the option closing, the total number of shares sold by the Company in the offering increased to 12,650,000 shares, which resulted in aggregate gross proceeds to the Company of approximately $151,800,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of our stockholders, employees and communities, the location of its 2020 annual meeting of stockholders (Annual Meeting) has been changed to a virtual meeting. As previously announced, the Annual Meeting will be held on June 5, 2020 at 10:00 a.m. Eastern Time, but will be held via live audio webcast. Stockholders will be able to attend the Annual Meeting only via the webcast.
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of an underwritten public offering of 11,000,000 shares of common stock at a public offering price of $12.00 per share. Gross proceeds to the Company from the offering are expected to be $132,000,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock in connection with the offering. All shares are being sold by the Company. The offering is expected to close on May 14, 2020, subject to the satisfaction of customary closing conditions. The offering was upsized from the previously announced offering size of approximately $100,000,000 of shares of common stock.
Shares of Akebia Therapeutics (NASDAQ: AKBA) were skyrocketing 37.3% higher as of 11:25 a.m. EDT on Tuesday. The huge jump came after the biotech announced positive results from a late-stage clinical study for its lead pipeline candidate vadadustat and reported its first-quarter financial results. The most important news for Akebia by far was its clinical update for vadadustat.
AKBA earnings call for the period ending March 31, 2020.
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the underwriters of its previously announced public offering, which closed on May 14, 2020, h…
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the commencement of a proposed underwritten public offering of approximately $100,000,000 of shares of its common stock. All shares being offered are to be sold by the Company. The Company also intends to grant the underwriters a 30-day option to purchase up to approximately $15,000,000 of additional shares of its common stock.
Biopharma Akebia Therapeutics (AKBA) skyrocketed 38% in Tuesday’s trading after reporting positive topline data from the global Phase 3 clinical trials of vadadustat.This is the company’s investigational oral hydroxylase inhibitor (HIF-PHI) for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.In the INNOVATE study (dialysis-dependent patient population) of over 3,900 patients; vadadustat achieved both its primary efficacy and cardiovascular safety endpoints.The treatment demonstrated non-inferiority to darbepoetin alfa as measured by a mean change in hemoglobin (Hb) between baseline and the primary and secondary evaluation periods. It also achieved the primary safety endpoint, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events (MACE).“We believe the data is positive” summed up Mizuho Securities analyst Difei Yang following the announcement. She has a buy rating on the stock and a $15 price target. Even following the stock’s rapid ascent, her price target still indicates upside potential of 26%.Looking forward, John P. Butler, Akebia CEO stated, “The team is already at work on vadadustat’s New Drug Application (NDA), which we expect to file as quickly as possible following the top-line data readout of PRO2TECT, our global Phase 3 program studying vadadustat in adult patients not on dialysis with anemia due to CKD, which we expect in mid-2020, as planned.”According to Needham’s Chad Messer, studies in CKD patients who are not on dialysis represents a far larger market opportunity for Akebia. “This [Protect] study design differentiates vadadustat from its primary competitor Astra Zenca’s roxadustat which was tested versus placebo in this population” he notes.Overall the stock scores a bullish Strong Buy analyst consensus. The average analyst price target stands at $14.17 (19% upside potential). (See Akebia stock analysis on TipRanks)Related News: Novavax (NVAX) Receives Bullish Praise From a Wall Street Pro Pfizer, BioNTech Shares Rise on U.S. Coronavirus Vaccine Trial Start Amarin (AMRN) Stock Could Stage a Rebound to $15, Says Analyst More recent articles from Smarter Analyst: * Waymo Raises $3 Billion In Extended Financing Round * Intel, Taiwan Semiconductor Said to Be in Talks with Trump to Build U.S. Plants * 3M Holds Good On Its Promise To Prioritize Dividend * Boeing Gets No Orders in April, Customers Cancel 737 MAX Jets
Structures of 5-lipoxygenase (5-LOX) reveal that NDGA disturbs regions that shield the active site while AKBA binds an allosteric site. NDGA inhibits 5-LOX activity using its redox-active function, while AKBA changes the enzyme’s regiospecificity
Seth Klarman’s 13F portfolio value decreased from $9.06B to $6.77B this quarter.Baupost Group increased eBay, HP, and ViacomCBS while dropping Bristol-Myers Squibb and Synchrony Financial. They also added large positions in Alphabet and Facebook during the qu…
Biopharma Akebia Therapeutics (AKBA) skyrocketed 38% in Tuesday’s trading after reporting positive topline data from the global Phase 3 clinical trials of vadadustat.This is the company’s investigational oral hydroxylase inhibitor (HIF-PHI) for the treatment …
Company hits 52-week high of $12.25 Continue reading...
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the commencement of a proposed underwritten public offering of approximately $100,000,000 of share…
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced plans to release its financial results for the first quarter ended Ma…
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental…
Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
As you might know, Akebia Therapeutics, Inc. (NASDAQ:AKBA) just kicked off its latest quarterly results with some very...